sorafenib has been researched along with Carcinoma, Ehrlich Tumor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Attia, AA; El-Magd, MA; El-Naggar, SA; Eldiasty, JG; Elmetwalli, A; Mosallam, SAE; Nasser, HM; Salama, AF | 1 |
| Abd-Alhaseeb, MM; Abou-El-Ela, SH; Moustafa, YM; Zaitone, SA | 1 |
2 other study(ies) available for sorafenib and Carcinoma, Ehrlich Tumor
| Article | Year |
|---|---|
Amygdalin potentiates the anti-cancer effect of Sorafenib on Ehrlich ascites carcinoma and ameliorates the associated liver damage.
Topics: Amygdalin; Animals; Antioxidants; Ascites; Carcinoma, Ehrlich Tumor; Liver; Matrix Metalloproteinase 9; Mice; Neoplasms; NF-E2-Related Factor 2; Sorafenib; Superoxide Dismutase; Vascular Endothelial Growth Factor A | 2022 |
Olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma: role of angiotensin (1-7).
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Female; Imidazoles; Immunohistochemistry; Insulin-Like Growth Factor I; Mice; Neovascularization, Pathologic; Niacinamide; Peptide Fragments; Phenylurea Compounds; Receptor, IGF Type 1; Sorafenib; Tetrazoles; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |